Evenamide Hydrochloride

Newron Pharmaceuticals has received regulatory approval for its ENIGMA-TRS Phase III program evaluating Evenamide as an add-on therapy for treatment-resistant schizophrenia, with patient recruitment beginning immediately.

Newron Pharmaceuticals has partnered with Myung In Pharm for the development and commercialization of evenamide in South Korea, contributing to a Phase III trial.

Newron Pharmaceuticals reported positive results for evenamide in treatment-resistant schizophrenia (TRS) from Phase II trials, demonstrating significant improvements in symptoms.

Bristol-Myers Squibb has agreed to acquire Karuna Therapeutics for $14 billion, gaining rights to KarXT, a first-in-class muscarinic receptor agonist for schizophrenia awaiting FDA approval.